Maximising commercial value across the product lifecycle
Strategic insights and planning to drive commercial success at every stage.
GRA delivers business intelligence and strategic planning to support clients across all commercial aspects of their programs. Whether it's ensuring robust preparedness for fundraising discussions or facilitating successful licensing agreements, our specific expertise in performing risk-adjusted Net Present Value (rNPV) assessments (alongside other AI based assisted tools), which account for the inherent uncertainties of drug development, provides a crucial advantage.
Business Intelligence
Business intelligence involves the collection and analysis of market data, competition, licensing opportunities and regulatory landscapes. This information informs the strategic direction of the business. In addition, the intelligence underpins risk management and allows the business leaders to make confident, evidence-based decisions across development and investment timelines.
Market & Competition Analysis
Market and competition analysis evaluates unmet needs, emerging technologies and competitor positioning. Furthermore, it supports innovation and helps identify areas of strategic opportunity. Building a thorough understanding of competitive landscapes improves decisions around differentiation, timelines and commercial positioning.
Pricing Analysis
The analysis of pricing and value positioning of medicines help ensure a product is not mis-priced or poorly differentiated. Effective pricing strategies must be built on market evidence, payer expectations and benchmarking. This supports accurate valuation, risk mitigation and long-term commercial viability.
Portfolio
The portfolio analysis considers the balance and alignment of assets across development stages and therapeutic areas. It involves strategic prioritisation based on scientific promise, market need as well as timing. If managed, the product portfolio supports the long-term vision of the business while allowing greater agility around evolving scientific and commercial risks.
Licensing
Licensing strategy requires understanding deal structures, risk-sharing models and asset valuation. Regardless of whether in-licensing or out-licensing, clear expression of an asset's value, its timelines and its data supports successful negotiations. Licensing assessments must align with strategic goals as well as include due diligence on competitor assets.
Clinical & Commercial Supply Agreements
Supply agreements support product availability through clinical trials and into the market. Planning ensures both appropriate scalability and continuity of supply. The agreement must be fair to both parties, include realistic timelines as well as risk mitigation throughout the development and launch phases. Ultimately the agreements must be a win-win for both parties to remain viable.
Quality Control (QC)
Developed methods are used routinely to test products produced in manufacturing facilities working to Good Manufacturing Practice (GMP) guidelines. QC methods are critical for ensuring that the integrity and quality of the biopharmaceutical throughout their development lifecycle.
Download this information here.
For more information on how we help, click here.